Orris

ivabradine cause atrial fibrillation

Reading File
Checking Date & Time
Finding Sources
Searching PubMed

ivabradine AND "atrial fibrillation"

Reading File
Reading File
Reading File
Yes — ivabradine is associated with an increased risk of atrial fibrillation (AF). Here is a comprehensive breakdown:

Ivabradine and Atrial Fibrillation

Mechanism

Ivabradine selectively blocks HCN (hyperpolarization-activated cyclic nucleotide-gated) channels — specifically the funny current (I_f) — in the sinoatrial (SA) node. This slows the spontaneous depolarization rate, reducing heart rate only in patients in sinus rhythm. It has no effect on AV conduction, contractility, or ventricular repolarization.
The AF risk is thought to arise because:
  • The I_f current is present not just in the SA node but also in atrial myocytes. Modulation of these channels may promote atrial ectopy or alter atrial electrophysiology.
  • Ivabradine does not suppress ectopic foci in the atria — unlike β-blockers, which have broader antiarrhythmic coverage.

Clinical Evidence

Study/SourceFinding
BEAUTIFUL trialIn patients with stable CAD + normal LV function, ivabradine added to β-blockers conferred no benefit but increased rates of bradycardia, AF, and QT prolongation (Fox et al., 2014)
SHIFT trialIvabradine in HFrEF reduced heart failure hospitalizations, but an increased incidence of AF was observed as an adverse event
Meta-analysis (2024, PMID 39425897)In acute heart failure, ivabradine efficacy/safety analysis confirmed AF as a notable adverse effect

Key Clinical Implications

  1. Contraindicated in existing AF: Ivabradine only works in sinus rhythm — since its mechanism requires SA node activity, it provides no rate control in AF. Using it in AF is both ineffective and potentially harmful.
  2. AF risk during therapy: Patients on ivabradine have a documented increased risk of developing AF. If AF occurs, ivabradine should be discontinued.
  3. Not a β-blocker substitute: It lacks the broader antiarrhythmic and sympatholytic properties of β-blockers, which is one reason it does not protect against AF.
  4. Caution with QT-prolonging agents: Should not be combined with amiodarone or other QT-prolonging drugs.

Prescribing Safeguards

  • Screen ECG before initiation — confirmed sinus rhythm is mandatory.
  • Monitor for symptoms of palpitations or new-onset AF during treatment.
  • Discontinue if AF develops.
  • Avoid in patients with a history of AF or high AF risk.
Sources:
  • Lippincott Illustrated Reviews: Pharmacology — Adverse Effects, ivabradine
  • Goldman-Cecil Medicine — Sinus Node Inhibitors: Ivabradine
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics — Ivabradine
This is a shared conversation. Sign in to Orris to start your own chat.